1 week Ago By ABMN Staff
Prudential Financial Inc. grew its position in shares of Puma Biotechnology, Inc. ( NASDAQ:PBYI – Free Report ) by 5.
8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,285 shares of the biopharmaceutical company’s stock after buying an additional 5,800 shares during the quarter. Prudential Financial Inc.
’s holdings in Puma Biotechnology were worth $324,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co.
boosted its holdings in Puma Biotechnology by 169.5% in the 3rd quarter. JPMorgan Chase & Co.
now owns 48,493 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 30,499 shares during the period. SG Americas Securities LLC grew its stake in shares of Puma Biotechnology by 83.9% in the 4th quarter.
SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 11,252 shares during the period. FMR LLC grew its position in Puma Biotechnology by 27.1% in the third quarter.
FMR LLC now owns 118,265 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 25,183 shares during the period. Barclays PLC raised its stake in Puma Biotechnology by 146.5% during the third quarter.
Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock worth $199,000 after acquiring an additional 46,370 shares in the last quarter. Finally, Franklin Resources Inc. bought a new position in shares of Puma Biotechnology during the third quarter valued at $41,000.
61.29% of the stock is currently owned by institutional investors and hedge funds. Wall Street Analyst Weigh In Several analysts have weighed in on PBYI shares.
HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, February 28th. StockNews.
com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 8th. Puma Biotechnology Price Performance Puma Biotechnology stock opened at $2.74 on Friday.
The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.
46. The firm has a market capitalization of $135.93 million, a P/E ratio of 5.
71 and a beta of 1.34. The business has a 50-day moving average of $3.
09 and a 200-day moving average of $3.00. Puma Biotechnology, Inc.
has a 1 year low of $2.23 and a 1 year high of $5.65.
Puma Biotechnology ( NASDAQ:PBYI – Get Free Report ) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.
10 by $0.29. Puma Biotechnology had a return on equity of 41.
60% and a net margin of 9.56%. The business had revenue of $59.
10 million for the quarter, compared to the consensus estimate of $52.50 million. On average, equities analysts anticipate that Puma Biotechnology, Inc.
will post 0.31 EPS for the current year. Puma Biotechnology Company Profile ( Free Report ) Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. See Also Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology, Inc.
( NASDAQ:PBYI – Free Report ). Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter .
.
